PHARMA & LIFE SCIENCES BRIEFING: OFFICE AND LAB OCCUPANCY BENCHMARKS
See how your offices and labs really compare.
A private, 30-minute briefing for workplace, CRE and R&D operations teams in pharma and life sciences. We’ll show you how peers measure lab space utilization alongside their offices, what lab occupancy sensors can and can’t tell you, and how that data is ending up in capital decisions.
Find out:
- How office and lab utilization really compare across a two-speed pharmaceuticals portfolio, and why one target can’t cover a write-up floor and a lab that runs through the night
- How leading pharmaceuticals teams map labs down to bench and equipment level, so sites can be compared globally
- The workplace technology and use case roadmaps other pharmaceuticals CRE teams are running ahead of consolidation, renovation and capacity decisions.
- Trusted worldwide
The world's leading pharma and life sciences teams choose XY Sense
Office spaces optimized by real-time data
Global scale, compliance,
deployment support.
Precision live data you can see & trust
Annual occupancy detections powering enterprise decisions
WHAT'S THE OFFER?
A 30-minute pharma workplace strategy briefing from the people who handle this data every day.
FIRST 10 MINS
Lab utilization benchmarks vs. your peers
Office & Lab Benchmarks vs. Industry Peers
What live occupancy looks like on both sides of a pharma portfolio.
On the office side we cover desk utilization ranges, meeting room demand against supply, and how hard the Tuesday to Thursday peak compresses. On the lab side we cover what a headcount at the lab door tells you, what bench-level measurement tells you, and why they rarely agree. A lab can look full on badge data and still have benches nobody has used all week, because each group kept its own.
NEXT 10 MINS
Lab occupancy sensors: use cases and rollout roadmaps
Compare Use Cases & Roadmaps
How other pharma workplace and R&D operations teams have sequenced this.
Where they put threshold sensors at lab entries to get a simple headcount, and where they paid for overhead coverage down to individual benches, fume hoods and biosafety cabinets. How they named and grouped lab space so one site could be compared with another. How occupancy data got into the same data lake as equipment logs, the BMS and the asset register. And what they’d do differently.
Most teams end up with a mix. Closed rooms like cell culture suites often only need a count. Open labs with shared equipment usually justify more. We’ll show you the bronze, silver and gold versions and what each one answers.
We share patterns, not names, but with the sequencing detail you won’t find in a case study.
FINAL 10 MINS
Lab equipment utilization analysis for your portfolio
Uncover Quick Wins & Validate Your Theses
Most teams arrive with a working theory. Scientists say there isn’t enough bench space. A group wants two more fume hoods. An office floor is quiet four days out of five. Finance wants the consolidation case closed by year end.
We’ll tell you where the data usually lands on those, what lab installs really involve in regulated environments, and what a business case needs to contain to survive your own finance review.
Who will be briefing me?
You’ll be talking to people who do this all week.
You’ll be briefed by whichever of them covers your region — each one runs XY Sense in their market, so they know how workplace decisions actually get made where you are. And because they stay with customers long after deployment, they can tell you what didn’t work as readily as what did.
Jane Watson, Head of EMEA
Came to workplace via investment banking, venture philanthropy and growth operations for global SaaS firms. Works with XY Sense’s UK and European customers on workplace transformation built entirely on anonymous, real-time data.
Shivaun Ryan, Head of Americas
More than a decade in PropTech, IoT and workplace strategy. Works with enterprise leaders across 20+ countries on space, sustainability and the future of work. Based in New York.
Jared Horstman, Head of APAC
Ten years leading teams in InfoSec, identity management and IoT before workplace analytics — so he can take your security team’s questions as readily as your CRE team’s. Works with enterprise workplace leaders across Australia and Asia Pacific.
Ashish Singh, Head of India
20 years across India’s workplace solutions landscape. Rare depth on how workplace decisions actually get made in India — the priorities, the processes and the people involved.
Between them they’ve been through the security, privacy, site access and compliance processes at some of the world’s largest pharmaceuticals and life sciences companies. That includes lab installs in controlled environments, so the questions your InfoSec, EHS and procurement teams will ask are ones they’ve answered before.
- Ready to talk?
Book your complimentary pharma & life sciences occupancy benchmarks briefing
30 minutes.
A real person who knows lab and office data.
And no death by PowerPoint (we promise).
How teams like yours are creating impact
Three pharma and life sciences teams we work with, and what their occupancy data changed.
At one global pharma company, XY Sense data now informs the design of every office and lab space in its real estate portfolio. It has become part of how the company measures workplace productivity, and how it checks that each space actually meets the needs of the teams using it.
It started with a headcount at the doors of two new office-and-lab buildings, 22 floors in all, where some floors were packed while others sat empty. When the company moved from two to three in-office days, the data showed which teams belonged where, and teams were moved across floors to sit closer to the spaces and equipment they use.
Then it put lab occupancy sensors inside the labs. Which equipment gets used most, where the high-traffic zones are and how long people spend in each area now shape how its future labs are laid out.
Health and safety teams watch nine or ten air-quality indicators live. When construction next door pushed levels below acceptable limits, staff were sent home that day.
The rollout has grown from those two buildings to 18 sites in eight countries, and the workplace team uses the reports daily, including when it takes confident, data-backed recommendations to the C-suite on the future of its CRE portfolio.
A global biopharma company wanted evidence on how workplace conditions affect its people, with local teams and headquarters planning from the same data. Occupancy and indoor air quality (CO₂, particulates, VOCs, temperature, humidity and noise) sit in one platform, connected to building operations and room booking. Booked rooms that stay empty release automatically, and an unbooked room that’s in use gets checked in. HVAC and lighting follow where people actually are. Because both data sets sit together, the team can check whether a rise in CO₂ on a floor lines up with a change in how it’s being used.
A global pharma business needed an objective view of how its offices were used, and the numbers had to compare cleanly across Europe, India, the US and Japan. Anonymous sensors in six offices measure floor entries, per-seat desk use, meeting-room no-shows and space types. Site dashboards roll up into executive reporting, and the data now feeds decisions on new builds, fit-outs and whether to renew or consolidate leases. Processing happens on the sensor and no personal data is collected, so one rollout approach worked across several privacy regimes.
Do these problems sound familiar?
You’re running two portfolios under one budget, and they don’t behave anything alike.
All of these problems are solvable. Just not from systems (like access cards and Wi-Fi) that were never built to measure occupancy in the first place.
Your portfolio runs at two speeds.
Offices went hybrid. Labs didn't, and many run through the night. One sits half empty on a Friday while the other is booked at 2am, and a single utilization target describes neither.
The patent cliff lands on your cost line.
When revenue faces loss of exclusivity, site consolidation and opex cuts come up fast, and real estate is one of the first places leadership looks. You need a number that survives that conversation.
Lab space gets defended by whoever argues hardest.
Every lab feels at capacity and every instrument feels essential. Equipment monitoring usually covers a small share of assets, and scientists will rightly say an empty bench doesn't mean the instrument isn't mid-run. Benches, write-up desks and shared kit have no data at all.
Every change to a validated space costs time.
Change control, requalification, documentation. You can't trial a new layout the way an office team can, so you need to know it's right before you move anything.
You have plenty of data and not much confidence in it.
Badge swipes, booking tools, lease schedules, EHS logs, equipment monitoring, headcount forecasts. Lots of records, no shared definition of "used", and almost nothing on what happens at the bench.
Your 2030 lab is being designed this year.
Sensor positions have to work around ceiling services, tall equipment and utility drops, and the cabling and gateways go in with the build. If occupancy data is an afterthought, you'll be retrofitting a finished lab.
Five things our pharmaceutical occupancy benchmarks show
From the latest Workplace Utilization Index — 63,000+ workspaces. A sample of what we’ll walk you through, and where pharmaceutical portfolios sit against these global enterprise trends.
Peak days run at nearly double the quiet ones
Tuesday utilization reaches 52% globally. Friday holds at 30%. That 22-point gap has stayed stable across multiple consecutive editions of the Index — which means planning off a weekly average gets both ends of the week wrong at once.
Demand has moved to enclosed space. Most supply is still open plan.
Meeting rooms average 56% utilization. Phone booths and pods reach 52%. Individual focus settings sit at 48%. Open, unwalled collaboration areas — the centrepiece of a decade of workplace redesign — average just 30%.
Meeting rooms are sized for a meeting that rarely happens.
94% of meetings involve six or fewer people, and nearly 40% involve just one — typically a video call or a focused work block that needs acoustic separation, not scale. Rooms built for 10 to 14 people average three actual occupants per session. Rooms for 20 to 29 average four.
Most portfolios are still over-indexed toward desks.
Offices continue to be configured for a level of desk demand that current workplace behaviour no longer supports, while the smaller enclosed spaces people actually rely on stay undersupplied. It's a mix problem before it's a footprint problem.
Friction concentrates exactly where supply is thinnest.
Short meetings cluster on Tuesday and Wednesday, driving high turnover and sustained demand for small rooms across the week. Peak-day demand for enclosed formats is where shortage is felt — and it's the part a weekly average is structurally incapable of showing you.
Lab equipment sits idle more than most people think.
In one CBRE monitoring program, lab prep bench use was 2-4% and average equipment utilization was 7%. Agilent puts average instrument use at around 35%. We'll show you where occupancy data fits in.
- Why listen to us?
Most occupancy advice is built on surveys. Ours is built on measurement.
Industry benchmarks are typically assembled from questionnaires, badge exports and four-week sampling studies. They tell you what people said, what doors opened, or what one month looked like.
XY Sense sensors measure continuously, at the edge, across every space type in the portfolio — every two seconds, to approximately 99% accuracy, to one-foot positional precision. That produces something the category doesn’t otherwise have: a live, continuous, like-for-like record of how enterprise offices are genuinely used across time.
When we brief you, we’re not summarizing someone else’s industry report. We’re reading our own primary data and sharing the aggregated insights that are most useful.
- Frequently asked questions
Is this actually a sales call?
No, and we’ve structured it so it can’t quietly become one. There’s no product walkthrough unless you ask for one. If at the end you want to see the platform, we’ll book that separately. Plenty of briefings end with people taking the note away and doing nothing — that’s a fine outcome for us.
Do we have to share our data?
No. Bring as much or as little as you like. If you have utilisation figures you’d like read against the benchmarks, bring them. If you’d rather just listen, the first two-thirds work without any input from you.
We're already contracted with another vendor.
Then the briefing is more useful, not less. A significant share of the Financial Services teams we brief are mid-contract and trying to work out what to do at renewal — coverage economics, accuracy thresholds, integration debt. We’ll be straight with you about where a switch isn’t worth the disruption.
We already have badge and wifi data.
Most teams do. The briefing covers exactly what those sources can and can’t tell you, and where the measurement gap sits. It’s usually wider than expected — but it’s a real answer, not a setup.
Who should attend from our side?
One person is fine. It tends to be more valuable with two or three — typically CRE, workplace, and someone from workplace technology or IT, because the questions come from different directions.
We're not going to do anything for 12 months.
That’s often the best time to have it. Most of what we cover is about how to sequence a programme, which is more useful before a budget cycle than during one.